Eli Lilly in pact with Chinese biotech for novel weight loss therapy

Indianapolis - April 2016: Eli Lilly and Company VII

jetcityimage/iStock Editorial via Getty Images

Chinese biotech Laekna Therapeutics on Wednesday announced a clinical collaboration with Eli Lilly (NYSE:LLY) to develop an obesity therapy that can avoid loss of muscle mass, a problem often linked to LLY’s weight loss therapy, tirzepatide.

Shanghai-based Laekna said the

Leave a Reply

Your email address will not be published. Required fields are marked *